SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor-sector selloff, amplified by SOXLs 3x daily leverage, has fueled attention; LAM Researchs warning about component supply constraints added to concerns around AI-chip demand and heavy AI spending. Traders are divided between viewing the drop as an oversold washout and expecting further losses, while debating whether semiconductor and AI growth remains intact or is being repriced.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

A leak of Phase 3 results for Moderna and Mercks personalized melanoma vaccine triggered a sharp selloff: the data showed a benefit alongside Keytruda, but traders say it fell short of expectations built into the stocks steep rally. Bulls argue the clinical results remain strong and the drop is an overreaction, while bears focus on valuation and whether the treatment can scale commercially.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong Q3 results and raised outlook have been overshadowed by a sharp selloff, with traders debating negative cash flow and heavy capital spending against high expectations and weakness in AI-related stocks. Bulls see the spending as investment in capacity for growing power demand, while skeptics question valuation and whether growth will translate into cash.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

A steep pullback from recent highs is dominating discussion, with traders pointing to broader market and sector selling alongside higher oil and jet-fuel costs amid Middle East tensions. Some see the companys fundamentals and share buybacks as reasons to stay bullish, while others question the weakness and warn of further downside.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPEs sharp rebound and gains alongside a broader meme-coin rally are driving attention, with traders cheering for another leg higher. Others question the moves staying power, pointing to thin volume, repeated resistance, and choppy consolidation; no specific news catalyst is established.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers quarterly update has drawn attention after revenue missed expectations and management cut its sales outlook amid price-conscious shoppers and heavier footwear promotions, despite raising earnings guidance. Traders are divided between viewing the selloff as an overreaction given profitability and buybacks, and focusing on weaker growth and the cautious outlook.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas sharp selloff and fresh lows are being tied by traders to plans to explore a separate listing for fintech unit Monee and launch Sea Cloud, raising concerns about spending, execution and how a listing could affect existing shareholders. Some see Monee as a source of potential value, while others view the plans as added uncertainty amid a severe technical downturn.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Bullish analyst initiations are drawing attention to Celcuitys commercial opportunity for FDA-approved REVTORPYK, with traders also highlighting a potential PIK3CA-mutant label expansion. Optimism about the drugs market potential is balanced by debate over whether the early launch can translate into meaningful prescription and revenue growth.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

A sharp semiconductor selloff has put SMH under pressure, with traders pointing to supply-chain concerns and doubts about whether AI infrastructure spending and financing can sustain chip demand. The community is split between fears that the AI trade is unraveling and dip buyers looking for an oversold bounce near support.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digitals strong quarterly results and upbeat outlook were met with a sharp share decline, prompting traders to debate whether the selloff reflects a broader retreat from AI-linked stocks or concerns about higher capital spending and a potentially cyclical peak outweighing robust storage demand. Some see the reaction as an overdone sell-the-news move, while others question how durable current growth and pricing will be.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Analysts Estimate Incyte (INCY) to Report a Decline in Earnings: What to Look Out for

Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

Incyte (Nasdaq:INCY) today announced that it will present new data from its oncology portfolio during the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. The data being presented at ESMO further reinforce our confidence in these novel...

VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes

Equity

On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose. 


Incyte to Report Third Quarter Financial Results

Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Thursday, October 29, 2026. The schedule for the press release and conference call/webcast is as follows: Q3 2026 Press Release: October 29, 2026, at 7:00...

If You Invested $1000 In Incyte Stock 15 Years Ago, You Would Have This Much Today

Incyte (NASDAQ:INCY) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 14.45%. Currently, Incyte has a market capitalization of $22.70 billion.read more...

If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much Today

Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.48% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $23.82 billion.read more...

INCY or TECH: Which Is the Better Value Stock Right Now?

INCY vs. TECH: Which Stock Is the Better Value Option?

MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy

Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.

LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss

Eli Lilly's Olumiant wins FDA nod to treat pediatric patients 12 years of age and older with severe alopecia areata, expanding its U.S. use after strong phase III results.

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary MiniMed appoints Sheila Denton as General Counsel & Corporate SecretaryPR NewswireNORTHRIDGE, Calif., Sept. 28, 2026 NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes...

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Incyte Corp.

Bearish Sentiment

<ul class="summary-bullets"><li>Alliance Global on Thursday raised its price target on VSTM to $22 from $18 and maintained a Buy rating.</li><li>RBC Capital analyst Leonid Timashev said that while VS-7375 tolerability is not as favorable as Revolution Medicines’ experimental drug Zoldonrasib, the overall profile remains acceptable.&nbsp;</li><li>BTIG said VS-7375 could rival Revolution Medicines’ approved drug Daraxonrasib in second-line metastatic pancreatic disease.</li></ul> Shares of Verastem Oncology (VSTM) jumped 20% on Thursday, clocking its best day since Nov. 2025, as analysts lifted price targets following a positive update on the company’s experimental drug VS-7375 in second-line metastatic pancreatic ductal adenocarcinoma.On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose, along with responses in lung and colorectal cancers and a manageable safety profile dominated by low-grade gastrointestinal side effectsVerastem also added that the company has aligned with the U.S. Food and Drug Administration on a late-stage path in first-line metastatic pancreatic cancer using chemotherapy-free regimens, with the study expected to open by year-end.<h2 class="st-heading-2">Wall Street Weighs In On VSTM</h2>Alliance Global on Thursday subsequently raised its price target to $22 from $18 and maintained a Buy rating, describing the updated TARGET-D 101 data as showing a highly tolerable safety profile and efficacy that is in line with or better than other drugs in the same class and in development, potentially best-in-class.RBC Capital analyst Leonid Timashev increased the target to $19 from $14 while keeping an Outperform rating, calling the drug clearly active with hints of best-in-class efficacy in pancreatic ductal adenocarcinoma. He noted that while tolerability is not as favorable as one competitor, Revolution Medicines’ experimental drug Zoldonrasib, the overall profile remains acceptable.BTIG raised its target to $24 from $18 and kept a Buy rating, saying the detailed update across second-line pancreatic cancer, second-line non-small cell lung cancer, and third-line colorectal cancer points to class-leading efficacy that could rival Revolution Medicines’ approved drug Daraxonrasib in second-line metastatic pancreatic disease.Jefferies analyst Faisal Khurshid raised the price target to $13 from $11 and maintained a Buy rating. Aligning on a favorable late-stage trial path, he added, positions Verastem only about seven months behind competitors Revolution Medicines and Incyte in the race to develop drugs within the same class.<h2 class="st-heading-2">CEO Change And Capital Raising</h2>Verastem on Wednesday also priced a $250 million offering of common stock and pre-funded warrants at $8 per share to support VS-7375 development and general purposes, expected to close around October 15.The company further announced a planned CEO transition, with longtime executive Daniel Paterson retiring effective January 1, 2027, and board member Michael P. Bailey succeeding him.<h2 class="st-heading-2">How Did VSTM Retail Traders React?</h2>On Stocktwits, retail sentiment around VSTM stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.“The more I watch it, the more constructive it looks,” a Stocktwits user wrote about the stock.<stembedurl>https://stocktwits.com/topstockalerts/message/666627602</stembedurl>Another user drew a parallel between VSTM’s current rally and Iovance Biotherapeutics Inc (IOVA) stock’s rally last month, which lasted for several days.<stembedurl>https://stocktwits.com/Always_neutral/message/666623781</stembedurl><a class="mention" data-mention="$VSTM" data-symbol-id="VSTM" href="https://stocktwits.com/symbol/VSTM" target="_blank">VSTM stock</a> has gained 2o% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mrna-stock-hits-fresh-52-week-highs-as-goldman-raises-target-ahead-of-melanoma-data/cZxh3NsRBrS">MRNA Stock Hits Fresh 52-Week Highs As Goldman Raises Target Ahead Of Melanoma Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose. 

Revolution Medicines Inc

Verastem Inc

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Current Price	$116.93
Prev Close	$113.44
Open	$113.93
Dividend Yield	0.00%
50-Day Moving Average	$121.36
Beta	0.52
Avg. Volume	1.54M
PE Ratio	14.90

52-Week High	$132.60
52-Week Low	$84.02
Market Capitalization	$23.7B
EPS (Annual)	$6.41
Price to Book	3.70
Revenue Per Employee	$1.81M

Feed

News

Sentiment

Earnings

Fundamentals

Info

INCY Fundamentals